Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthonics Inc.

This article was originally published in Start Up

Executive Summary

Orthonics has developed a way, using nanotechnology fabrication techniques, of creating a microarchitecture on the surface of a hydrogel or polymer such that its physical shape induces bone and cartilage precursor cells to differentiate into cells that produce bone and cartilage. Its first product will be a device for the repair of a damaged annulus of the spine.

You may also be interested in...



Spine-Bending Market

Today, the market for spine surgery is growing by more than 20% annually based on fusion technologies alone, despite the fact that those technologies are decades old and flawed. However, a heightened awareness of the clinical drawbacks of fusion is fueling prolific company creation in a new spine motion preservation segment of the industry. Some 118 start-ups in spine are dotting the landscape. Many hope to offer new devices that address spinal joint reconstruction; artificial discs, disc nuclei, annulus repair, facet joint replacement, and dynamic or flexible stabilization of the spine.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

Topics

Related Companies

UsernamePublicRestriction

Register

OM003971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel